Eli Lilly

The Phase 3 study compared abemaciclib in combination with an aromatase inhibitor versus an aromatase inhibitor alone in patients with HR+, HER2- advanced breast cancer INDIANAPOLIS, April 24, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of demonstrating […]

INDIANAPOLIS, April 20, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will highlight Phase 2 data evaluating galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting, which will take place April 22-28, 2017, in Boston. Lilly will present four abstracts at AAN, including safety and patient outcomes data for […]

INDIANAPOLIS APRIL 14, 2017–(BUSINESS WIRE)– Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA). The letter […]

Lilly scholarship donations total more than $1.3 million since 2008 INDIANAPOLIS, ARLINGTON, Va. and ROLLING MEADOWS, Ill., April 7, 2017 /PRNewswire/ — Living with type 1 diabetes comes with many unique challenges in all stages of life. For parents of children with the condition, financial, medical and emotional worries can be overwhelming. To help support […]

INDIANAPOLIS, April 4, 2017 /PRNewswire/ — Students from Ohio University’s Heritage College of Osteopathic Medicine will soon join Eli Lilly and Company’s (NYSE: LLY) innovative rotation program for aspiring physicians. Launched in early 2014, the program provides students with hands-on experience in a range of pharmaceutical business activities, from drug discovery and development to bioethics and […]

Significant investment in manufacturing diabetes medicines continues with new $85 million commitment in Indianapolis $5 billion invested in its U.S. operations over the last decade; more favorable tax climate could lead to additional U.S. investments INDIANAPOLIS, March 24, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced plans to invest $850 million in its […]

Jointly developed research projects will study diabetes healthcare outcomes for the Latino population SANTA BARBARA, Calif. and INDIANAPOLIS, March 23, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and the William Sansum Diabetes Center have established a research collaboration to improve the lives of Latino people affected by diabetes through enhanced research, education and care. […]

Abemaciclib, in combination with fulvestrant, was superior to fulvestrant plus placebo in patients with HR+, HER2- advanced breast cancer INDIANAPOLIS, March 20, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated abemaciclib, a cyclin-dependent […]

EMPEROR HF clinical trial program will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes Heart failure affects 26 million people worldwide, and 5.7 million people in the U.S., and is associated with high morbidity and mortality EMPEROR HF will include approximately 7,000 […]

Lilly to present head-to-head 24-week data comparing the efficacy and safety of Taltz and Stelara for the treatment of moderate-to-severe plaque psoriasis INDIANAPOLIS, March 4, 2017 /CNW/ — Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe plaque psoriasis treated with Taltz® (ixekizumab) demonstrated superior efficacy at 24 weeks compared to patients […]